C-myc gene is a member of the myc family of protooncogenes involved in proliferation, differentiation, and apoptosis. Overexpression of c-myc in fibroblasts causes apoptosis under low serum conditions in a process that requires the interaction of CD95 and CD95L on the surface. We have previously reported an in vivo conditional model to inactivate the c-myc gene in B lymphocytes. Here, we show that c-Myc-deficient primary B lymphocytes are resistant to different apoptotic stimuli. Nonactivated c-Myc-deficient B cells are resistant to spontaneous cell death. Upon activation, c-Myc-deficient B lymphocytes express normal surface levels of activation markers, and show resistance to staurosporine and CD95-induced cell death.
Introduction
Myc proteins are basic region/helix-loop-helix/leucine zipper (bHLHZip) transcription factors involved in cell proliferation, differentiation, and apoptosis. [1] [2] [3] [4] [5] One of its members, c-Myc, is expressed from immature stages of B-cell differentiation, and is rapidly induced upon mitogenic stimulation. [6] [7] [8] Overexpression of c-myc induces apoptosis in fibroblasts and myeloid cell lines in low serum conditions. 1,2,9 More recently, Hueber et al. 10 have shown that c-Myc-induced apoptosis in fibroblasts requires the interaction on the cell surface of CD95, a member of the TNF receptor family, and its ligand CD95L, triggering an apoptotic pathway that activates a set of cysteine proteases, called caspases, which lead to cell death. 11 In T-cell hybridomas, anti-CD3-induced cell death is mediated by CD95 and CD95L, and is prevented by the inhibition of c-Myc expression. [12] [13] [14] [15] Moreover, inhibition of activation-induced cell death (AICD) by TGFb correlates with downregulation of surface CD95L, a process mediated by c-myc in T-cell lines. 16, 17 In B lymphocytes, downmodulation of c-myc expression correlates with induction of apoptosis in B-cell lines. [18] [19] [20] Anti-CD40 stimulation of B lymphocytes induces the surface expression of CD95 and makes them susceptible to cell death by this receptor. [21] [22] [23] Furthermore, addition of interleukin 4 to anti-CD40-activated B lymphocytes renders these cells more resistant to CD95-induced cell death. 24 Inactivation of c-myc gene in the germ line results in embryonic lethality at day 9.5. 24 We have previously reported the generation of a conditional in vivo model to study c-myc function in B lymphocytes. 25 Now, we have bred c-myc fl/fl ; CD19 cre with a ROSA26-EGFP 'reporter' mouse, in order to circumvent the problems associated with incomplete deletion of the c-myc gene, [25] [26] [27] and extended our studies to characterize the role of c-myc in programmed cell death in primary B lymphocytes. Upon activation, c-Myc-deficient B lymphocytes express normal surface levels of activation markers, and are more resistant to CD95 and staurosporineinduced cell death. Finally, resistance to CD95-induced cell death correlates with lower levels of surface expression of CD95 and CD95L.
Results
Generation of c-myc fl/fl ; CD19 cre ; egfp mice
We have previously reported the generation of mouse model to study c-myc function in B lymphocytes. In this in vivo model, approximately 60-70% of splenic B cells show deletion of the c-myc gene. 25 Therefore, we designed a strategy to isolate cmyc-deleted B cells from a mixed population of deleted and nondeleted B cells from c-myc fl/fl ; CD19 cre mice. With this aim, we crossed c-myc fl/fl ; CD19 cre mice with a 'knockin' reporter mouse expressing the green fluorescence protein (GFP) under the endogenous promoter of the rosa26 gene (egfp). 26, 27 Expression of Cre recombinase from the CD19 endogenous locus would lead to specific deletion of both cmyc locus and the stop codon inserted in the egfp gene in B lymphocytes. This strategy would potentially allow us to select and isolate c-Myc-deficient B cells that express GFP.
We found that approximately 40% of B220 þ B cells (13.9% of total splenocytes) also expressed GFP in homozygous c-myc fl/fl ; CD19 cre ; egfp mice (fl/fl mice from hereafter) (Figure 1a ). To test whether expression of GFP correlated with c-myc deletion, we purified splenic B220 þ GFP þ B lymphocytes from homozygous fl/fl, and heterozygous c-myc In heterozygous þ /fl mice, we observed that 81% (44.2% of total splenocytes) of the B220 þ cells expressed also GFP. This higher number of B220 þ GFP þ B cells in heterozygous mice might represent a proliferative advantage of cells carrying a wt allele of c-myc, and it is consistent with our previous observations in c-myc þ /fl ; CD19 cre mice. 25 Genomic analysis by PCR of sorted B220 þ GFP þ B lymphocytes from heterozygous þ /fl mice also revealed the deletion of the 'floxed' allele, and therefore these B cells are c-myc þ /n ( Figure 1a and b, n allele) . Furthermore, PCR analysis of DNA from B220 þ GFP þ B cells from heterozygous þ /fl and homozygous fl/fl mice did not show the presence of 'floxed' alleles after 48 h of activation with anti-CD40 plus interleukin 4 ( Figure 1b) . Consequently, expression of GFP in B lymphocytes from heterozygous þ /fl and homozygous fl/fl mice correlates with deletion of the c-myc gene in these cells.
In contrast, PCR analysis of cell-sorted B220 þ GFPÀ B cells from homozygous fl/fl and heterozygous þ /fl mice revealed the presence of deleted (n allele) and nondeleted alleles (floxed, fl) likely coming from c-myc-deleted and nondeleted cells that do not express GFP (Figure 1b) .
Finally, thymidine incorporation experiments performed with sorted B220 þ GFP þ B lymphocytes did not reveal differences in cell proliferation capacity between c-myc
, and wt B cells. These results suggest that GFP expression in B lymphocytes did not interfere with cell proliferation (data not shown).
C-Myc-deficient B lymphocytes are more resistant to CD95-, and staurosporine-induced cell death Hueber et al. showed that c-myc-induced apoptosis in fibroblasts required the interaction of CD95 and CD95L in a process that relies on the release of cytochrome C from the mitochondria. 10, 28 Therefore, to determine whether the CD95 apoptotic pathway was affected in c-Myc-deficient B lymphocytes, we activated B220 þ GFP þ c-myc n/n and c-myc þ /n B lymphocytes with anti-CD40 antibody or anti-CD40 plus interleukin 4 for 48 h before inducing cell death with increasing concentrations of sCD95L.
At 48 h after activation with anti-CD40, we observed that c-myc n/n B cells were more resistant to CD95-induced cell ; egfp) mice. Freshly isolated B lymphocytes from spleen were stained with anti-B220 monoclonal antibody and purified by cell sorting (495% purity) using double-staining (B220 þ GFP þ ) and/or single-staining (B220 þ GFP-) gates. (b) PCR analysis of c-myc alleles of B lymphocytes sorted as indicated in (a). At 0 h, cell sorting and PCR analysis were performed on the B-cell populations indicated in (a), or unsorted total spleen was used from the different genotypes. B220 þ GFP þ , and B220 þ GFPÀ B cells from heterozygous þ /fl and homozygous fl/fl mice, and B220 þ GFPÀ wt B lymphocytes were activated in vitro for 48 h with anti-CD40 antibody (10 mg/ml) plus interleukin 4 (20 ng/ml) before harvesting the cells for PCR analysis (40 cycles) of the c-myc gene. PCR strategy to distinguish c-myc alleles is indicated below. death than control c-myc þ /n B lymphocytes, upon treatment with sCD95L or anti-CD95 antibody ( Figure 2a , Table 1 ).
The presence of interleukin 4 confers resistance to CD95-induced cell death in CD40-stimulated primary B cells. 29, 30 We observed interleukin 4-dependent resistance to CD95-induced cell death in c-myc þ /n B lymphocytes ( Figure 2a , Table 1 ). In the case of c-myc n/n B lymphocytes, we observed IL-4-dependent resistance, although less significant than control c-myc þ /n B lymphocytes. More importantly, treatment with sCD95L or anti-CD95 antibody still results in more resistance to cell death in c-myc n/n B lymphocytes than heterozygous c-myc þ /n B lymphocytes ( Figure 2a , Table 1 ) after activation with anti-CD40 antibody or anti-CD40 plus interleukin 4. Consequently, this result suggests that the lack of the c-myc gene contributes to resistance to CD95-induced cell death independently of interleukin 4-mediated resistance. Interestingly, nonactivated c-Myc-deficient B cells are also more resistant to spontaneous cell death than nonactivated controls (Figure 2a and b) .
Staurosporine is a potent inhibitor of protein kinase C (PKC), that preferentially activates the mitochondrial apoptotic pathway. 31 To test whether c-Myc-deficient B lymphocytes were also resistant to a different apoptotic stimuli, we treated them with staurosporine. Sorted B lymphocytes were activated with anti-CD40 antibody or anti-CD40 plus interleukin 4 and culture for 48 h before adding staurosporine. In Table 1 , we observed that activated c-Myc-deficient B lymphocytes were more resistant to staurosporine-induced cell death than control B lymphocytes.
Finally, to test whether resistance to CD95-induced cell death in c-Myc-deficient B lymphocytes was due to a non-fully functional CD95L receptor, we performed a CD95L-mediated cytotoxic assay. 32 In Figure 3 , we observed that activated c-myc n/n B lymphocytes were capable of killing A20 target cells as well as control B lymphocytes (43.5 versus 44.0%, respectively, for 20 : 1 E : T ratio). Leakiness of cell tracker from A20 cells to primary B cells is unlikely since no GFP þ CTÀorange þ (cell tracker) double-positive cells were present in the cultures (Figure 3b , data not shown). This result suggests that CD95L in c-Myc-deficient B cells is functional to interact with CD95 and induce cell death through this receptor.
c-Myc-deficient B cells express low levels of surface CD95 upon stimulation with anti-CD40 or anti-CD40 plus interleukin 4
We have previously reported that c-Myc-deficient B lymphocytes expressed normal levels of activation markers, and lower levels of CD95 and CD95L, upon stimulation with anti-CD40 plus interleukin 4. 25 To find out whether c-myc n/n B lymphocytes from fl/fl mice express surface markers normally induced upon activation with anti-CD40 and anti-CD40 plus interleukin 4, we performed FACS analysis on cell-sorted B220 þ cells.
In Figure 4a and b, we show that c-myc n/n B lymphocytes express normal surface levels of CD25 and CD69 upon activation with anti-CD40 or anti-CD40 plus interleukin 4, when compared to c-myc þ /n B lymphocytes. However, we observed decreased CD95 surface expression in anti-CD40 and anti-CD40 plus interleukin 4-activated c-myc n/n B lymphocytes. In the case of CD95L, we detected a modest decrease in surface expression in c-myc n/n B lymphocytes upon treatment with anti-CD40 plus interleukin 4 only. Different activation thresholds could account for differences in the surface expression of CD95L versus CD95 receptor. To characterize whether decreased surface expression of CD95 and CD95L correlated with changes in the transcriptional levels of these genes, we performed RT-PCR analysis on activated (B220 þ GFP þ ) c-Myc-deficient B lymphocytes. We did not detect any significant difference (o 2fold) on the transcriptional levels of CD95 and CD95L between c-myc n/n and c-myc þ /n B lymphocytes activated with anti-CD40 or anti-CD40 plus interleukin 4 ( Figure 5a ).
Resistance to CD95-induced cell death has been correlated with expression of the inhibitor of apoptosis c-Flip. C-Flip interacts with the adaptor protein FADD and the protease FLICE (caspase 8) inhibiting CD95-mediated cell death in lymphoid cells. 33 Therefore, RT-PCR analysis was performed to see whether expression of c-flip gene was affected in c-Myc-deficient B lymphocytes. No differences in c-flip gene expression were (otwo-fold) observed between c-Mycdeficient B lymphocytes and heterozygous controls (Figure 5a ). We concluded from these experiments that c-Myc does not regulate c-flip, cd95, and cd95l gene expression in primary B lymphocytes.
CD95 surface levels are reduced in (B220 þ GFP þ ) c-myc n/n B cells activated with anti-CD40 or anti-CD40 plus interleukin 4. Decreased surface expression of CD95 has been reported to confer resistance to CD95-induced cell death. 34 Engagement of CD95 receptor on the surface leads to the activation of procaspase 8, caspase 3, 35 and ultimately to cleavage of the caspase 3 substrate poly (ADP-ribose) polymerase (PARP). 36 To determine whether higher resistance to anti-CD95-induced cell death in c-Myc-deficient cells correlated with changes in PARP processing, we performed Western blot analysis on these cells. In Figure 5b , we show that c-myc n/n B lymphocytes have decreased PARP protein processing when compared with controls.
Discussion
We have previously reported the generation of a conditional mouse model to study c-myc function in B lymphocytes. In this previous model, analysis of c-Myc-deficient B cells was hampered by incomplete deletion of c-myc gene in all B lymphocytes. Therefore, to overcome these problems, we bred c-myc fl/fl ; CD19 cre mouse with a reporter mouse that expresses GFP upon cre-mediated deletion. In this report, we have shown that deletion of c-myc gene correlates with expression of GFP in B lymphocytes. We also observed c-myc-deleted cells in B lymphocytes that do not express GFP (B220 þ GFPÀ cells) (Figure 1a and b) . We did not detect cells that express GFP and carry nondeleted c-myc alleles. Recently, Vooijs et al. 37 have shown that Cre-mediated recombination is locus dependent. Consequently, lack of GFP expression in c-myc-deleted cells might be due to different accessibilities of the Cre recombinase to different loci (c-myc versus rosa26).
CD95/CD95L is induced in normal B cells following treatment with anti-CD40, leading to susceptibility to apoptosis via the CD95 pathway. [21] [22] [23] Our results show that mitogenstimulated, c-Myc-deficient B lymphocytes are more resistant to CD95-induced cell death, and express low surface levels of CD95 and CD95L when compared to control cells (Figure 4a and b) . Noteworthy is the fact that c-Myc-deficient B cells express normal surface levels of activation markers like CD69 or CD25, showing that they are capable of receiving Same numbers of sorted B lymphocytes were activated with either anti-CD40 antibody (10 mg/ml) or anti-CD40 plus interleukin 4 (20 ng/ml). At 48 h after stimulation, cells were either treated with anti-CD95 antibody (+aCD95, 100 ng/ml, Jo2 Pharmigen) or staurosporine (+Staur, Sigma, 20 nM), or nontreated (À). The table shows percentages of cell death (sub-G0/G1 values) by propidium iodide staining of six independent experiments. ND, not done activation signals (Figure 4a and b) . One possibility is that reduced CD95 or CD95L surface expression could account for resistance to CD95-induced cell death, as previously reported in T cells. 34 In addition, CD95 resistance is accompanied by decreased processing of PARP protein, which would be consistent with a lower activation of the CD95 apoptotic pathway in c-Myc-deficient B cells (Figure 5b) . In contrast to cd95l gene expression in T-cell hybridomas, 16 we did not observe transcriptional regulation of cd95, cd95l or c-flip genes by c-Myc in B lymphocytes (Figure 5a ).
Taken together, our results cannot conclude whether decreased CD95/CD95L surface expression results from a direct role for c-Myc in regulating the surface expression of these proteins, or is due to a defect in B-cell activation. In the context of a direct effect, we can speculate that c-Myc is affecting the surface expression of CD95, and to lesser extent CD95L, by regulating the transport of these molecules to the membrane in B lymphocytes. However, c-Myc-deficient B cells also show resistance to staurosporine-induced cell death. This result would suggest a more general role of c-myc in sensitizing the cells to cell death to different apoptotic stimuli, rather than specifically regulating the surface expression of CD95 or CD95L. In addition, spontaneous cell death is reduced in c-Myc-deficient B lymphocytes. This is particularly striking, since the levels of c-Myc in resting B cells are very low compared to activated B lymphocytes. One possible explanation is that when deletion of c-myc gene occurs at any stage of B-cell differentiation, the cell is already sensitized to apoptotic stimuli. In this context, a nonactivated c-Myc-deficient B lymphocyte would be more resistant that a wt B lymphocyte.
Materials and Methods

Mice
The generation of the c-myc fl/fl CD19 cre mice has been described previously. 25 Briefly, c-myc fl/fl CD19 cre mice were bred with ROSA26-EGFP mice, 26 and progeny bred to yield homozygous c-myc fl/fl ;CD19 cre ; egfp mice (fl/fl) or heterozygous c-myc
cre ; egfp mice ( þ /fl). Mice were genotyped using a PCR-based analysis of tail genomic DNA.
Genomic PCR and RT-PCR analysis
Primers used to amplify floxed undeleted (flox, 530 bp) and deleted ( n , 600 bp) c-myc alleles were (a) TAAGAAGTTGCTATTTTGGC, (b) (TTTTCTTTCCGATTGCTGAC), (c) TCGCGCCCCTGAATTGCTAGGAA, and (d) TGCCCAGATAGGGAGCTGTGATACTT, respectively. Primers lac-Z1 GTGGTGGTTATGCCGATCG and lac-Z2 TACCACAGCGGAT GGTTCGG were used to amplify the ROSA26-EGFP allele. Gapdh gene was amplified using GAPDH5 0 CATCACCATCTTCCAGGAGC and GAPDH3 0 CATGAGTCCTTCCACGATACC primers. For RT-PCR analy- 
Cell sorting and cell culture conditions
All experiments were done with purified B cells by cell sorting (495% purity). Briefly, single-cell suspensions from spleens were stained with anti-B220 monoclonal antibody (Southern Biotechnology Association). Subsequently, B lymphocytes were sorted by flow cytometry (Coulter cell sorter), based on the surface expression of B220 þ (wt cells) or B220 þ GFP þ double-positive B cells ( þ /n or n/n cells). After sorting, the purity was monitored by FACS, and was usually 495% or more (data not shown). Sorted B lymphocytes (10 6 cells/ml) were cultured in RPMI (15% FCS) with anti-CD40 antibody (10 mg/ml, Pharmingen) and interleukin 4 (20 ng/ml, RD) for 48 h at 371C. B cells were either treated with anti-CD95 antibody (21) Antibodies and CD95L staining Antibodies All antibodies for FACS are from Pharmingen. We used directly PEconjugated antibodies for CD95, CD25, CD69 and isotypic control PE antibodies. For CD95L staining, we used IgG2b, k-PE as isotypic control, FcBlock and biotinylated anti-CD95L (Kay 10). H11 antibody from Alexis corporation (clone H11) was also used to detect CD95L surface expression (data not shown). Streptavidin-PE was used with biotinylated antibodies (Southern Biotechnology).
CD95L staining
We followed the protocol described in Lundy and Boros. 38 Briefly, B cells were first incubated 10 min at 41C with 1 ml/well of FcBlock (Pharmigen, 0.5 mg/ml). After washing, biotinylated CD95L antibody (Kay 10, 0.5 mg/ well) or isotypic control (0.5 mg/well) was added, and incubated at 41C for 30 min. After washing with PBS (2% FCS), streptavidin-PE was added, and incubated at 41C for 20 min. Cells were resuspended in PBS (2% FCS) and analyzed by FACS.
Western Blotting
Activated sorted B cells were harvested 90 min after anti-CD95 antibody was added. Protein extracts were prepared in a NP40 buffer (50 mM TrisHCl,pH 7.5, 5 mM EDTA, 150 mM NaCl and 1% NP-40) with protease inhibitors (1 mM PMSF, 10 mg/ml aprotinin, 10 mg/ml leupeptin, 1 mg/ml pepstatin). Lysates were size-fractionated in 7% SDS-PAGE. Western blots were performed by standard methods, using a monoclonal anti-PARP antibody (LABGEN) followed by HRP-conjugated anti-mouse IgG antibody (DAKO).
Cell death detection
Sorted cells were cultured as described above. Cell death was induced at 48 h postactivation by adding sCD95L kit (Alexis corporation), and monitored using Cell Death Detection ELISA plus (cat.# 1774425, Roche). The assay is based on a quantitative sandwich-enzyme-immunoassay principle, using monoclonal antibodies directed against DNA and histones. This allows the specific determination of mono and oligonucleosomes in the cytoplasmatic fraction of cell lysates.
To monitor for cell death with anti-CD95 antibody or staurosporine (subG0/G1 fraction), the treated cells were permeabilized and stained with propidium iodide for 30 min at 37şC using DNA-Prep reagents kit (Beckman Coulter, cat.#PN6607055) before analysis by FACS.
Cytotoxicity assay A20 target cells described in Maleguine et al. 32 (murine B lymphoma cell line) were labeled with a cell tracker (CT-orange, Molecular Probes) to distinguish them from primary B lymphocytes. B cells were sorted from total spleen suspension based on GFP expression. Sorted GFP þ c-myc n/n and c-myc þ /n B lymphocytes were cultured as described above, at 10 6 cells/ml. The effector cells (activated sorted B cells) were incubated with labeled target cells (CT-orange, Molecular Probes) (10 4 A20 cells/well) at various E : T ratios. The mixed cells were incubated at 371C for 20 h. Samples were stained with annexin-V (Immunotech), and analyzed by FACScan for the detection of apoptotic cells. A20 cells (dead and alive, data not shown) were CTÀorange þ . Primary B cells were GFP þ . Therefore, based on CTÀorange expression, we distinguished A20 dead cells in the population of Annexin þ cells.
